Ind-Swift Laboratories Ltd. (IN:INDSWFTLAB)
:INDSWFTLAB
Top Page
Ind-Swift Laboratories Ltd.
(INDSWFTLAB)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹162.00
▲(78.61% Upside)
Action:ReiteratedDate:04/09/26
Overall score is driven primarily by solid balance-sheet strength and strong revenue growth, tempered by significant cash flow weakness (negative operating and free cash flows). Technicals are supportive with an uptrend and positive momentum, while valuation appears moderate based on the P/E, with no dividend yield data to add support.
Positive Factors
Revenue Growth
Sustained revenue growth of ~25.6% indicates expanding product adoption and market penetration in the pharmaceutical segment. Durable top-line expansion provides a base for scale, supports coverage of fixed costs and R&D, and improves the company's ability to invest in long-term capabilities.
Negative Factors
Negative Operating & Free Cash Flow
Persistent negative operating and free cash flows undermine the company's ability to self-fund operations, capex and R&D. Over months, this can force reliance on external financing or equity, increasing funding cost and diluting strategic flexibility essential for a pharma firm.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth of ~25.6% indicates expanding product adoption and market penetration in the pharmaceutical segment. Durable top-line expansion provides a base for scale, supports coverage of fixed costs and R&D, and improves the company's ability to invest in long-term capabilities.
Read all positive factors
Ind-Swift Laboratories Ltd. (INDSWFTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹11.51B
Dividend YieldN/A
Average Volume (3M)7.30K
Price to Earnings (P/E)18.9
Beta (1Y)1.12
Revenue Growth-37.70%
EPS Growth-19.79%
CountryIN
Employees47
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.17
Shares Outstanding81,611,560
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.96
P/FCF Ratio-5.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ind-Swift Laboratories Ltd. Business Overview & Revenue Model
Company Description
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic,...
How the Company Makes Money
null...
Ind-Swift Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.22B | 5.62B | 12.81B | 12.07B | 10.39B | 8.91B |
| Gross Profit | 4.19B | 2.74B | 4.13B | 4.40B | 4.10B | 3.75B |
| EBITDA | 3.05B | 2.85B | 7.82B | 2.36B | 2.35B | 1.98B |
| Net Income | 2.66B | 2.50B | 4.21B | 475.97M | -21.49M | -31.47M |
Balance Sheet | ||||||
| Total Assets | 15.44B | 14.38B | 14.60B | 18.24B | 18.01B | 18.18B |
| Cash, Cash Equivalents and Short-Term Investments | 4.33B | 4.82B | 4.94B | 231.54M | 333.68M | 116.01M |
| Total Debt | 220.47M | 408.41M | 166.22M | 8.62B | 9.53B | 10.05B |
| Total Liabilities | 2.37B | 2.65B | 6.48B | 11.42B | 12.00B | 12.15B |
| Stockholders Equity | 13.07B | 11.73B | 9.36B | 6.82B | 6.01B | 6.04B |
Cash Flow | ||||||
| Free Cash Flow | -472.94M | -898.80M | -2.08B | 1.82B | 1.32B | 1.31B |
| Operating Cash Flow | -202.50M | -254.74M | -1.63B | 1.95B | 1.50B | 1.35B |
| Investing Cash Flow | -1.04B | -1.10B | -1.23B | -133.68M | 47.72M | -101.72M |
| Financing Cash Flow | 961.18M | 692.05M | 6.99B | -1.86B | -1.41B | -1.24B |
Ind-Swift Laboratories Ltd. Technical Analysis
Positive
90.70
Price Trends
135.61
Positive
115.92
Positive
110.13
Positive
Market Momentum
1.93
Positive
51.85
Neutral
57.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Positive. The current price of 90.7 is below the 20-day moving average (MA) of 140.56, below the 50-day MA of 135.61, and below the 200-day MA of 110.13, indicating a bullish trend. The MACD of 1.93 indicates Positive momentum. The RSI at 51.85 is Neutral, neither overbought nor oversold. The STOCH value of 57.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDSWFTLAB.
Ind-Swift Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹13.29B | 10.01 | ― | ― | 13.32% | 218.38% | |
66 Neutral | ₹12.94B | 22.21 | ― | ― | 24.20% | 55.01% | |
65 Neutral | ₹11.51B | 18.86 | ― | ― | -37.70% | -19.79% | |
63 Neutral | ₹3.56B | 19.99 | ― | ― | -5.82% | -59.22% | |
55 Neutral | ₹3.29B | 56.53 | ― | 0.26% | -9.16% | 49.09% | |
52 Neutral | ₹2.65B | 7.63 | ― | ― | -30.27% | -3470.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
141.05
54.67
63.29%
IN:MEDICAMEQ
Medicamen Biotech Limited
242.45
-250.07
-50.77%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.82
-10.96
-48.11%
IN:SAKAR
Sakar Healthcare Ltd
589.45
324.99
122.89%
IN:VENUSREM
Venus Remedies Limited
994.15
682.60
219.10%
IN:ZIMLAB
Zim Laboratories Ltd.
73.07
-14.93
-16.97%
Ind-Swift Laboratories Ltd. Corporate Events
Ind-Swift Laboratories Seeks Shareholder Nod for Major Leadership Restructuring via Postal Ballot
Mar 30, 2026
Ind-Swift Laboratories Ltd. has launched a postal ballot process to seek shareholder approval for several key board and management changes, underscoring a significant reshaping of its leadership structure across domestic and global operations. The...
Ind-Swift Labs Retains ₹19.66 Crore as 6.5 Million Warrants Lapse
Mar 1, 2026
Ind-Swift Laboratories has announced that 6.5 million fully convertible warrants previously allotted on a preferential basis to Saral Incorporated VCC Sub Fund 1 have lapsed after the investor did not exercise the option to convert them into equit...
Ind-Swift Labs Files CARE Monitoring Report on Rs 314.6 Crore Preferential Issue
Feb 3, 2026
Ind-Swift Laboratories Ltd. has disclosed that CARE Ratings Limited, acting as the independent monitoring agency, has issued its report for the quarter ended 31 December 2025 on the company’s preferential issue of equity capital aggregating ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.